Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

published on May 27, 2020 by Charlie Smith in CannCentral

Back in 2016, the peer-reviewed journal EMBO Reports published astonishing numbers on the financial fallout from mental disorders.

Three researchers at the Dresden University of Technology concluded that in 2010, the “global direct and indirect economic costs” were estimated at US$2.5 trillion.

“Mental disorders therefore account for more economic costs than chronic somatic diseases such as cancer or diabetes, and their costs are expected to increase exponentially over the next 15 years,” wrote Sebastian Trautmann, Jürgen Rehm, and Hans-Ulrich Wittchen.

Vancouver physician Evan Wood has been on the leading edge of research into the relationship between addiction and mental health for almost two decades.

In recent years, the adviser to the Global Commission on Drug Policy has seen an explosion of scientific interest in how psychedelic substances—such as MDMA and psilocybin—can be deployed in the treatment of mental illness, addiction, and posttraumatic stress disorder…